國立虎尾科技大學 |

Phase I Oncology Drug Development

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Phase I Oncology Drug Development/ edited by Timothy A. Yap, Jordi Rodon, David S. Hong.
其他作者:	Hong, David S.
面頁冊數:	X, 352 p. 47 illus., 45 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Oncology. -
電子資源:	https://doi.org/10.1007/978-3-030-47682-3
ISBN:	9783030476823

Phase I Oncology Drug Development
Phase I Oncology Drug Development[electronic resource] /edited by Timothy A. Yap, Jordi Rodon, David S. Hong. - 1st ed. 2020. - X, 352 p. 47 illus., 45 illus. in color.online resource.

Paradigm shift in oncology drug development -- Practicalities in setting up phase I trials -- Optimizing the preclinical development of antitumor agents for entry into phase I trials -- Considerations for the development of novel chemotherapies in phase I trials -- Considerations for the development of novel targeted agents in phase I trials -- Development of immunotherapeutic strategies in early phase clinical trials -- Assessment of radiotherapeutic strategies in phase I trials -- Development of combinatorial strategies in phase I trials -- Novel trial designs for early phase clinical trials -- Incorporating pharmacokinetic strategies for phase I trials -- Development of pharmacodynamic biomarkers for phase I trials -- Efficacy considerations for Phase I trials -- Incorporating precision medicine into Phase I clinical trials -- Molecular profiling of patients for clinical trials -- Incorporating circulating biomarkers into clinical trials -- Statistical considerations for early phase clinical trials -- Lessons from hematology for solid tumor drug development. .

This book provides a detailed review of how oncology drug development has changed over the past decade, and serves as a comprehensive guide for the practicalities in setting up phase I trials. The book covers strategies to accelerate the development of novel antitumor compounds from the laboratory to clinical trials and beyond through the use of innovative mechanism-of-action pharmacodynamic biomarkers and pharmacokinetic studies. The reader will learn about all aspects of modern phase I trial designs, including the incorporation of precision medicine strategies, and approaches for rational patient allocation to novel anticancer therapies. Circulating biomarkers to assess mechanisms of response and resistance are changing the way we are assessing patient selection and are also covered in this book. The development of the different classes of antitumor agents are discussed, including chemotherapy, molecularly targeted agents, immunotherapies and also radiotherapy. The authors also discuss the lessons that the oncology field has learnt from the development of hematology-oncology drugs and how such strategies can be carried over into therapies for solid tumors. There is a dedicated chapter that covers the specialized statistical approaches necessary for phase I trial designs, including novel Bayesian strategies for dose escalation. This volume is designed to help clinicians better understand phase I clinical trials, but would also be of use to translational researchers (MDs and PhDs), and drug developers from academia and industry interested in cancer drug development. It could also be of use to phase I trial study coordinators, oncology nurses and advanced practice providers. Other health professionals interested in the treatment of cancer will also find this book of great value. .

ISBN: 9783030476823

Standard No.: 10.1007/978-3-030-47682-3doiSubjects--Topical Terms:

593951
Oncology.

LC Class. No.: RC254-282

Dewey Class. No.: 616.994

Phase I Oncology Drug Development
LDR:04230nam a22003975i 4500 001 1029253
003 DE-He213
005 20200916100143.0
007 cr nn 008mamaa
008 210318s2020 gw | s |||| 0|eng d
020 $a 9783030476823 $9 978-3-030-47682-3
024 7 $a 10.1007/978-3-030-47682-3 $2 doi
035 $a 978-3-030-47682-3
050 4 $a RC254-282
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 616.994 $2 23
245 1 0 $a Phase I Oncology Drug Development $h [electronic resource] / $c edited by Timothy A. Yap, Jordi Rodon, David S. Hong.
250 $a 1st ed. 2020.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2020.
300 $a X, 352 p. 47 illus., 45 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
505 0 $a Paradigm shift in oncology drug development -- Practicalities in setting up phase I trials -- Optimizing the preclinical development of antitumor agents for entry into phase I trials -- Considerations for the development of novel chemotherapies in phase I trials -- Considerations for the development of novel targeted agents in phase I trials -- Development of immunotherapeutic strategies in early phase clinical trials -- Assessment of radiotherapeutic strategies in phase I trials -- Development of combinatorial strategies in phase I trials -- Novel trial designs for early phase clinical trials -- Incorporating pharmacokinetic strategies for phase I trials -- Development of pharmacodynamic biomarkers for phase I trials -- Efficacy considerations for Phase I trials -- Incorporating precision medicine into Phase I clinical trials -- Molecular profiling of patients for clinical trials -- Incorporating circulating biomarkers into clinical trials -- Statistical considerations for early phase clinical trials -- Lessons from hematology for solid tumor drug development. .
520 $a This book provides a detailed review of how oncology drug development has changed over the past decade, and serves as a comprehensive guide for the practicalities in setting up phase I trials. The book covers strategies to accelerate the development of novel antitumor compounds from the laboratory to clinical trials and beyond through the use of innovative mechanism-of-action pharmacodynamic biomarkers and pharmacokinetic studies. The reader will learn about all aspects of modern phase I trial designs, including the incorporation of precision medicine strategies, and approaches for rational patient allocation to novel anticancer therapies. Circulating biomarkers to assess mechanisms of response and resistance are changing the way we are assessing patient selection and are also covered in this book. The development of the different classes of antitumor agents are discussed, including chemotherapy, molecularly targeted agents, immunotherapies and also radiotherapy. The authors also discuss the lessons that the oncology field has learnt from the development of hematology-oncology drugs and how such strategies can be carried over into therapies for solid tumors. There is a dedicated chapter that covers the specialized statistical approaches necessary for phase I trial designs, including novel Bayesian strategies for dose escalation. This volume is designed to help clinicians better understand phase I clinical trials, but would also be of use to translational researchers (MDs and PhDs), and drug developers from academia and industry interested in cancer drug development. It could also be of use to phase I trial study coordinators, oncology nurses and advanced practice providers. Other health professionals interested in the treatment of cancer will also find this book of great value. .
650 1 4 $a Oncology. $3 593951
650 0 $a Radiotherapy. $3 593952
650 0 $a Oncology . $3 1253469
700 1 $a Hong, David S. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1325898
700 1 $a Rodon, Jordi. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1325897
700 1 $a Yap, Timothy A. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1325896
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783030476816
776 0 8 $i Printed edition: $z 9783030476830
776 0 8 $i Printed edition: $z 9783030476847
856 4 0 $u https://doi.org/10.1007/978-3-030-47682-3
912 $a ZDB-2-SME
912 $a ZDB-2-SXM
950 $a Medicine (SpringerNature-11650)
950 $a Medicine (R0) (SpringerNature-43714)